Skip to content

Study · Randomized controlled trial · 1989

6 results

Effect of salcatonin given intranasally on early postmenopausal bone loss.

Overgaard K, Riis BJ, Christiansen C, Hansen MA

BMJ (Clinical research ed.)1 Aug 1989Cited by 103 (Europe PMC)

PMID2507027 (opens in a new tab)PMCIDPMC1837347 (opens in a new tab)DOI10.1136/bmj.299.6697.477 (opens in a new tab)PepBankPUB-02507027
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal women, spinal bone mineral content was 3.8% higher with salcatonin than placebo after one year.

    In plain wordsIn early postmenopausal women, spinal bone mineral content was higher with salcatonin than placebo after one year.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseSpinal bone mineral content at one year
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU · intranasal · 1 yearAs given in this study (human).

    Measurements

    Between-group difference
    3.8%
    one year
    95% confidence interval
    0 to 7.6%
    one year

    Source sentences

    Summary
    After one year the difference was 3.8% (95% confidence interval 0.0 to 7.6%) and after two years it was 8.2% (3.8 to 12.6%).
    5 context sentences
    Summary · context
    Bone mineral content in the spine was significantly higher in the women who had received salcatonin than in those who had received placebo both after one year and after two years of treatment.
    Summary · context
    Double blind, placebo controlled, randomised group comparison.
    Summary · context
    52 Healthy women who had had a natural menopause two and a half to five years previously.
    Summary · context
    The 52 women were allocated randomly to two years of treatment with either salcatonin 100IU given intranasally (n = 26) or placebo (n = 26).
    Summary · context
    Both groups received a calcium supplement of 500 mg daily.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal women, spinal bone mineral content was 8.2% higher with salcatonin than placebo after two years.

    In plain wordsIn early postmenopausal women, spinal bone mineral content was higher with salcatonin than placebo after two years.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseSpinal bone mineral content at two years
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Between-group difference
    8.2%
    two years
    95% confidence interval
    3.8 to 12.6%
    two years

    Source sentences

    Summary
    After one year the difference was 3.8% (95% confidence interval 0.0 to 7.6%) and after two years it was 8.2% (3.8 to 12.6%).
    5 context sentences
    Summary · context
    Bone mineral content in the spine was significantly higher in the women who had received salcatonin than in those who had received placebo both after one year and after two years of treatment.
    Summary · context
    Double blind, placebo controlled, randomised group comparison.
    Summary · context
    52 Healthy women who had had a natural menopause two and a half to five years previously.
    Summary · context
    The 52 women were allocated randomly to two years of treatment with either salcatonin 100IU given intranasally (n = 26) or placebo (n = 26).
    Summary · context
    Both groups received a calcium supplement of 500 mg daily.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal women, distal forearm bone mineral content declined similarly with salcatonin and placebo, about 2% yearly.

    In plain wordsIn early postmenopausal women, distal forearm bone mineral content declined similarly with salcatonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeDistal forearm bone mineral content
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Annual bone mineral content decline
    ≈ 2%
    both groups

    Source sentences

    Summary
    In contrast, the bone mineral content in the distal and proximal forearms and in the total skeleton declined similarly in both groups by about 2% each year, and after two years of treatment the differences between the groups were not significant.
    4 context sentences
    Summary · context
    Double blind, placebo controlled, randomised group comparison.
    Summary · context
    52 Healthy women who had had a natural menopause two and a half to five years previously.
    Summary · context
    The 52 women were allocated randomly to two years of treatment with either salcatonin 100IU given intranasally (n = 26) or placebo (n = 26).
    Summary · context
    Both groups received a calcium supplement of 500 mg daily.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal women, proximal forearm bone mineral content declined similarly with salcatonin and placebo, about 2% yearly.

    In plain wordsIn early postmenopausal women, proximal forearm bone mineral content declined similarly with salcatonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeProximal forearm bone mineral content
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Annual bone mineral content decline
    ≈ 2%
    both groups

    Source sentences

    Summary
    In contrast, the bone mineral content in the distal and proximal forearms and in the total skeleton declined similarly in both groups by about 2% each year, and after two years of treatment the differences between the groups were not significant.
    4 context sentences
    Summary · context
    Double blind, placebo controlled, randomised group comparison.
    Summary · context
    52 Healthy women who had had a natural menopause two and a half to five years previously.
    Summary · context
    The 52 women were allocated randomly to two years of treatment with either salcatonin 100IU given intranasally (n = 26) or placebo (n = 26).
    Summary · context
    Both groups received a calcium supplement of 500 mg daily.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal women, total skeleton bone mineral content declined similarly with salcatonin and placebo, about 2% yearly.

    In plain wordsIn early postmenopausal women, total skeleton bone mineral content declined similarly with salcatonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeTotal skeleton bone mineral content
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Annual bone mineral content decline
    ≈ 2%
    both groups

    Source sentences

    Summary
    In contrast, the bone mineral content in the distal and proximal forearms and in the total skeleton declined similarly in both groups by about 2% each year, and after two years of treatment the differences between the groups were not significant.
    4 context sentences
    Summary · context
    Double blind, placebo controlled, randomised group comparison.
    Summary · context
    52 Healthy women who had had a natural menopause two and a half to five years previously.
    Summary · context
    The 52 women were allocated randomly to two years of treatment with either salcatonin 100IU given intranasally (n = 26) or placebo (n = 26).
    Summary · context
    Both groups received a calcium supplement of 500 mg daily.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal women, salcatonin did not affect biochemical estimates of bone turnover.

    In plain wordsIn early postmenopausal women, salcatonin did not affect biochemical estimates of bone turnover compared with placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeBone turnover
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Biochemical estimates of bone turnover were not affected by salcatonin.
    4 context sentences
    Summary · context
    Double blind, placebo controlled, randomised group comparison.
    Summary · context
    52 Healthy women who had had a natural menopause two and a half to five years previously.
    Summary · context
    The 52 women were allocated randomly to two years of treatment with either salcatonin 100IU given intranasally (n = 26) or placebo (n = 26).
    Summary · context
    Both groups received a calcium supplement of 500 mg daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.